Theodore R. Schroeder - 28 Feb 2022 Form 4 Insider Report for Nabriva Therapeutics plc (NBRVF)

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
NBRVF
Transactions as of
28 Feb 2022
Transactions value $
-$56
Form type
4
Date filed
02 Mar 2022, 18:51
Previous filing
08 Feb 2022
Next filing
08 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRVF Ordinary Shares Tax liability -$56 -125 -0.04% $0.45 314K 28 Feb 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.